CoChat

PAR2 Inhibition Enhanced the Sensitivity of Colorectal Cancer Cells to 5-FU and Reduced EMT Signaling

Open access
Quan, Qiuying, Zhong, Fengyun, Wang, Xinwei, Chen, Kai, Guo, Lingchuan · 2019 · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

The aim of this study was to investigate the underlying mechanisms that transforming growth factor-β (TGF-β)-mediated epithelial-to-mesenchymal transition (EMT) in tumor cells contributes to 5-FU resistance. A series of experiments involving cell viability and caspase activity analyses, siRNA transfection, RNA isolation, and quantitative-PCR (qPCR) assay, cell migration analysis, Western blotting analysis of total protein and membrane protein were performed in this study. Mouse xenograft model was used to determine the effect of the PAR2 inhibitor in vivo. In this study, we found that protease-activated receptor 2 (PAR2) induction in 5-FU therapy is correlated with TGF-β-mediated EMT and apoptosis resistance. PAR2 and TGF-β were both activated in response to 5-FU treatment in vivo and in vitro, and whereas TGF-β inhibition sensitized CRC cells to 5-FU and suppressed cell migration, PAR2 activation eliminated the effect of TGF-β inhibition. Conversely, siRNA-mediated PAR2 depletion or PAR2 inhibition with a specific inhibitor produced a similar phenotype as TGF-β signal inhibition: 5-FU sensitization and cell migration suppression. Moreover, the results of xenograft experiments indicated that the PAR2 inhibitor can enhance cell killing by 5-FU in vivo and suppress EMT signaling. Our results reveal that the TGF-β effects require the coordinating action of PAR2, suggesting that PAR2 inhibition could be a new therapeutic strategy to combat 5-FU resistance in CRC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3727/096504018x15442985680348

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Elevated transforming growth factor-β (TGF-β) and protease-activated receptor 2 (PAR2) expression among colorectal cancer CRC patients after 5-fluorouracil (5-FU) therapy. (A) Analysis of TGF-β and PAR2 in RNA extracted from CRC tumor biopsies before chemotherapy (before) and after chemotherapy (after). (B) Comparison of differences in TGF-β and PAR2 expression between aggressive and nonaggressive tumor tissues. (C) Analysis of MMP2, MMP9, and PAI-1 in RNA extracted from CRC tumor biopsies before chemotherapy (before) and after chemotherapy (after). *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 1 Elevated transforming growth factor-β (TGF-β) and protease-activated receptor 2 (PAR2) expression among colorectal cancer CRC patients after 5-fluorouracil (5-FU) therapy. (A) Analysis of TGF-β and PAR2 in RNA extracted from CRC tumor biopsies before chemotherapy (before) and after chemotherapy (after). (B) Comparison of differences in TGF-β and PAR2 expression between aggressive and nonaggressive tumor tissues. (C) Analysis of MMP2, MMP9, and PAI-1 in RNA extracted from CRC tumor biopsies before chemotherapy (before) and after chemotherapy (after). *p < 0.05, **p < 0.01, ***p < 0.001.CC BY-NC-ND · PubMed Central
Figure 2 5-FU treatment induces TGF-β and PAR2 expression and cell migration. (A) The indicated CRC cells were treated with 50 μg/ml of 5-FU for 24 h, and then cell viability was detected using the MTS assay. (B) CRC cells were treated as in (A), and then caspase 3/7 activity was analyzed. (C) CRC cells were processed as in (A), and TGF-β (left) and PAR2 (right) expression was examined using RT-PCR. (D) HCT116 and RKO cells were processed as in (A), after which the expression of the indicated proteins was analyzed through Western blotting. (E) HCT116 cells were processed as in (A), and then the expression of target genes was analyzed using RT-PCR. (F) HCT116 cells were processed as in (A), and the migration of the surviving cells after treatment was analyzed.
Figure 2 5-FU treatment induces TGF-β and PAR2 expression and cell migration. (A) The indicated CRC cells were treated with 50 μg/ml of 5-FU for 24 h, and then cell viability was detected using the MTS assay. (B) CRC cells were treated as in (A), and then caspase 3/7 activity was analyzed. (C) CRC cells were processed as in (A), and TGF-β (left) and PAR2 (right) expression was examined using RT-PCR. (D) HCT116 and RKO cells were processed as in (A), after which the expression of the indicated proteins was analyzed through Western blotting. (E) HCT116 cells were processed as in (A), and then the expression of target genes was analyzed using RT-PCR. (F) HCT116 cells were processed as in (A), and the migration of the surviving cells after treatment was analyzed.CC BY-NC-ND · PubMed Central
Figure 3 PAR2 coordinates with TGF-β to mediate 5-FU-triggered apoptosis and cell migration. (A) HCT116 cells were treated with 50 μg/ml of 5-FU after pretreatment for 1 day with 100 nmol/L LY2157299 and 100 U/ml trypsin, and then the expression of target proteins was analyzed through immunoblotting. (B) HCT116 cells were processed as in (A), and then cell survival was analyzed using the MTS assay. (C) HCT116 cells were processed as in (A), after which caspase 3/7 activity was analyzed. (D) HCT116 cells were processed as in (A), and the migration of the surviving cells after treatment was analyzed. (E) HCT116 cells transfected with pcDNA3.1 (control+) or pcDNA3.1-PAR2 (PAR2+) were treated with 50 μg/ml of 5-FU after pretreatment for 1 day with 100 nmol/L LY2157299, and then the expression of target proteins was analyzed through immunoblotting. (F) HCT116 cells were processed as in (E), and then cell survival was analyzed using the MTS assay. (G) HCT116 cells were processed as in (E), after which caspase 3/7 activity was analyzed. (H) HCT116 cells were processed as in (E), and the migration of the surviving cells after treatment was analyzed. *p < 0.05, **p < 0.01.
Figure 3 PAR2 coordinates with TGF-β to mediate 5-FU-triggered apoptosis and cell migration. (A) HCT116 cells were treated with 50 μg/ml of 5-FU after pretreatment for 1 day with 100 nmol/L LY2157299 and 100 U/ml trypsin, and then the expression of target proteins was analyzed through immunoblotting. (B) HCT116 cells were processed as in (A), and then cell survival was analyzed using the MTS assay. (C) HCT116 cells were processed as in (A), after which caspase 3/7 activity was analyzed. (D) HCT116 cells were processed as in (A), and the migration of the surviving cells after treatment was analyzed. (E) HCT116 cells transfected with pcDNA3.1 (control+) or pcDNA3.1-PAR2 (PAR2+) were treated with 50 μg/ml of 5-FU after pretreatment for 1 day with 100 nmol/L LY2157299, and then the expression of target proteins was analyzed through immunoblotting. (F) HCT116 cells were processed as in (E), and then cell survival was analyzed using the MTS assay. (G) HCT116 cells were processed as in (E), after which caspase 3/7 activity was analyzed. (H) HCT116 cells were processed as in (E), and the migration of the surviving cells after treatment was analyzed. *p < 0.05, **p < 0.01.CC BY-NC-ND · PubMed Central
Figure 4 PAR2 depletion sensitizes HCT116 cells to 5-FU treatment and limits cell migration. (A) HCT116 cells were transfected with PAR2 siRNA overnight and then treated with 50 μg/ml of 5-FU for 1 day; subsequently, immunoblotting was performed to examine the expression of the mentioned proteins. (B) HCT116 cells were processed as in (A), and then cell viability was analyzed using the MTS assay. (C) HCT116 cells were treated as in (A), and then caspase 3/7 activity was analyzed. (D) HCT116 cells were processed as in (A), after which RT-PCR was performed to analyze the expression of the genes of interest. (E) HCT116 cells were treated as in (A), and then the migration of the surviving cells after treatment was analyzed.
Figure 4 PAR2 depletion sensitizes HCT116 cells to 5-FU treatment and limits cell migration. (A) HCT116 cells were transfected with PAR2 siRNA overnight and then treated with 50 μg/ml of 5-FU for 1 day; subsequently, immunoblotting was performed to examine the expression of the mentioned proteins. (B) HCT116 cells were processed as in (A), and then cell viability was analyzed using the MTS assay. (C) HCT116 cells were treated as in (A), and then caspase 3/7 activity was analyzed. (D) HCT116 cells were processed as in (A), after which RT-PCR was performed to analyze the expression of the genes of interest. (E) HCT116 cells were treated as in (A), and then the migration of the surviving cells after treatment was analyzed.CC BY-NC-ND · PubMed Central
Figure 5 PAR2 inhibition produces similar effects as PAR2 depletion. (A) HCT116 cells were treated with 50 μg/ml of 5-FU together with/without 10 μmol/L ENMD-547 pretreatment for 1 day, after which the expression of the indicated proteins was examined through immunoblotting. (B) HCT116 cells were processed as in (A), and the expression of the indicated genes was analyzed using RT-PCR. (C) HCT116 cells were treated as in (A), and then cell survival was examined using the MTS assay. (D) HCT116 cells were processed as in (A), after which caspase 3/7 activity was analyzed. (E) HCT116 cells were processed as in (A), and then the migration of the surviving cells after treatment was analyzed.
Figure 5 PAR2 inhibition produces similar effects as PAR2 depletion. (A) HCT116 cells were treated with 50 μg/ml of 5-FU together with/without 10 μmol/L ENMD-547 pretreatment for 1 day, after which the expression of the indicated proteins was examined through immunoblotting. (B) HCT116 cells were processed as in (A), and the expression of the indicated genes was analyzed using RT-PCR. (C) HCT116 cells were treated as in (A), and then cell survival was examined using the MTS assay. (D) HCT116 cells were processed as in (A), after which caspase 3/7 activity was analyzed. (E) HCT116 cells were processed as in (A), and then the migration of the surviving cells after treatment was analyzed.CC BY-NC-ND · PubMed Central
Figure 6 PAR2 mediates the 5-FU tumor-killing effect and inhibition of cell migration in vivo. (A) Nude mice were subcutaneously injected with 1 × 106 wild-type HCT116 cells and, after 7 days, were intraperitoneally injected, once every 2 days for 10 days, with 50 mg/kg of 5-FU, 1 mg/kg of ENMD-547, or their combination. Tumor volume at specific times after treatment was evaluated; n = 5 per group. (B–D) Mice with HCT116 xenograft tumors were treated as in (A) for 4 consecutive days, and then tissue sections were stained for active caspase 3 (B), vimentin (C), and E-cadherin (D). **p < 0.01.
Figure 6 PAR2 mediates the 5-FU tumor-killing effect and inhibition of cell migration in vivo. (A) Nude mice were subcutaneously injected with 1 × 106 wild-type HCT116 cells and, after 7 days, were intraperitoneally injected, once every 2 days for 10 days, with 50 mg/kg of 5-FU, 1 mg/kg of ENMD-547, or their combination. Tumor volume at specific times after treatment was evaluated; n = 5 per group. (B–D) Mice with HCT116 xenograft tumors were treated as in (A) for 4 consecutive days, and then tissue sections were stained for active caspase 3 (B), vimentin (C), and E-cadherin (D). **p < 0.01.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 32

Metadata

Authors
Quan, Q., Zhong, F., Wang, X., Chen, K., & Guo, L.
Affiliations
  • First Affiliated Hospital of Soochow University (CN)
  • Second Affiliated Hospital of Soochow University (CN)
  • Nanjing Medical University (CN)
Venue
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
Published
2019-07-12
Volume
27
Issue
7
Pages
779-788
ISSN
0965-0407 (ISSN-L)
OpenAlex
W2922119917
Cited by
29
References
29
Citations by year
2026: 2 · 2025: 9 · 2024: 3 · 2023: 3 · 2022: 4 · 2021: 5 · 2020: 2 · 2019: 1
FWCI
0.99
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
protease-activated receptor 2, 5-fluorouracil resistance, colorectal cancer, epithelial-mesenchymal transition, TGF-beta signaling, apoptosis resistance, cell migration, chemosensitization, xenograft models
MeSH terms
Animals, Antineoplastic Combined Chemotherapy Protocols, Drug Synergism, Fluorouracil, Humans, Piperazines, RNA, Messenger, Transfection, Colorectal Neoplasms, Signal Transduction, Transforming Growth Factor beta, Apoptosis, Drug Resistance, Neoplasm, HT29 Cells, Xenograft Model Antitumor Assays, RNA, Small Interfering, Receptor, PAR-2, HCT116 Cells, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PAR2 Inhibition Enhanced the Sensitivity of Colorectal Cancer Cells to 5-FU and Reduced EMT Signaling. https://app.cochat.ai/papers/10.3727/096504018x15442985680348
The paper
Quan, Q., Zhong, F., Wang, X., Chen, K., & Guo, L. (2019). PAR2 Inhibition Enhanced the Sensitivity of Colorectal Cancer Cells to 5-FU and Reduced EMT Signaling. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. https://doi.org/10.3727/096504018x15442985680348

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.